Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815901 | 0.85 | MAPT (0.42) | KDM4EALDH1A1PARP1 | |
| SCHEMBL4814816 | 0.85 | ALDH1A1 (0.44) | KDM4EALDH1A1TDP1 | |
| SCHEMBL4817507 | 0.81 | MAPT (0.43) | KDM4EHRH3PARP1 | |
| SCHEMBL4807925 | 0.77 | KDM4E (0.48) | KDM4EALDH1A1TDP1HRH3PARP1 | |
| SCHEMBL23008455 | 0.74 | KDM4E (0.54) | KDM4EALDH1A1TDP1HRH3 | |
| SCHEMBL4817944 | 0.73 | CHKA (0.46) | KDM4EALDH1A1PARP1 | |
| SCHEMBL4820308 | 0.70 | RXRA (0.36) | KDM4EALDH1A1PARP1MAOB | |
| SCHEMBL20148587 | 0.69 | KDM4E (0.47) | KDM4EALDH1A1TDP1HRH3PARP1 | |
| SCHEMBL4816693 | 0.68 | CYP11B1 (0.52) | KDM4EPARP1 | |
| SCHEMBL4820201 | 0.68 | CYP19A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | KDM4E 1449/4885ALDH1A1 3901/4885TDP1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.